Fennec Pharmaceuticals Inc. (FENC) — SEC Filings
Fennec Pharmaceuticals Inc. (FENC) — 32 SEC filings. Latest: 8-K (Dec 9, 2025). Includes 18 8-K, 6 10-Q, 2 DEF 14A.
View Fennec Pharmaceuticals Inc. on SEC EDGAR
Overview
Fennec Pharmaceuticals Inc. (FENC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 9, 2025: Fennec Pharmaceuticals Inc. filed an 8-K on December 9, 2025, reporting on other events and financial statements. The company, previously known as Adherex Technologies Inc., is incorporated in British Columbia, Canada, and operates in the biological products sector.
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 1 bullish, 29 neutral, 2 mixed. The dominant filing sentiment for Fennec Pharmaceuticals Inc. is neutral.
Filing Type Overview
Fennec Pharmaceuticals Inc. (FENC) has filed 18 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G/A, 2 SC 13G, 1 8-K/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of FENC's 24 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $30,865,000 |
| Net Income | -$4,954,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $21,947,000 |
| Operating Margin | -11.9% |
| Total Assets | $49,261,000 |
| Total Debt | $18,206,000 |
Key Executives
- Mr. Raykov
- Mr. Hackman
- Dr. David M. Levinson
- Dr. Frederick W. Telling
- Dr. Adrian J. Wildfire
- Dr. Robert J. B. Davies
- Dr. Michael J. Yost
- Rostislav Raykov
Industry Context
Fennec Pharmaceuticals operates in the highly competitive and regulated pharmaceutical industry, focusing on orphan drugs. The market for rare disease treatments is growing, driven by unmet medical needs and advancements in biotechnology. However, companies in this space face significant R&D costs, lengthy approval processes, and pricing pressures from payers and competitors.
Top Tags
corporate-governance (4) · financials (4) · pharmaceuticals (4) · financial-reporting (3) · Fennec Pharmaceuticals (3) · Biopharmaceuticals (2) · Net Loss (2) · Cash Flow (2) · Licensing Agreement (2) · Oncology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| PEDMARK product sales, net (Q3 2025) | $12.46M | Increased from $6.97M in Q3 2024, showing strong product growth. |
| PEDMARK product sales, net (9M 2025) | $30.87M | Increased from $21.66M in 9M 2024, indicating consistent sales growth. |
| Net loss (Q3 2025) | $(638)K | Improved from $(5.74)M in Q3 2024, narrowing losses. |
| Net loss (9M 2025) | $(4.95)M | Compared to $1.55M net income in 9M 2024, primarily due to absence of licensing revenue. |
| Net cash used in operating activities (9M 2025) | $(6.51)M | Represents negative cash flow from core operations, a concern for liquidity. |
| Cash and cash equivalents (Sept 30, 2025) | $21.95M | Decreased from $26.63M at Dec 31, 2024, reflecting cash burn. |
| Upfront payment from Norgine | $43.00M | Key source of liquidity, providing funding for at least the next twelve months. |
| Accumulated deficit (Sept 30, 2025) | $224.64M | Indicates historical losses and ongoing challenge to achieve sustained profitability. |
| Common shares outstanding (Nov 10, 2025) | 28,116,829 | Reflects share count for per share calculations and market capitalization. |
| Net loss for Q2 2025 | $3.15M | Improved from $5.55M net loss in Q2 2024 |
| Net loss for H1 2025 | $4.32M | Compared to $7.28M net income in H1 2024 |
| PEDMARK product sales for H1 2025 | $18.40M | Increased from $14.68M in H1 2024 |
| Cash and cash equivalents at June 30, 2025 | $18.71M | Decreased from $26.63M at Dec 31, 2024 |
| Negative cash flow from operating activities for H1 2025 | $8.00M | Indicates significant cash burn |
| Accumulated deficit at June 30, 2025 | $223.99M | Reflects historical losses |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Fennec Pharmaceuticals Inc. (FENC)?
Fennec Pharmaceuticals Inc. has 32 recent SEC filings from Feb 2024 to Dec 2025, including 18 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of FENC filings?
Across 32 filings, the sentiment breakdown is: 1 bullish, 29 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Fennec Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Fennec Pharmaceuticals Inc. (FENC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Fennec Pharmaceuticals Inc.?
Key financial highlights from Fennec Pharmaceuticals Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for FENC?
The investment thesis for FENC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Fennec Pharmaceuticals Inc.?
Key executives identified across Fennec Pharmaceuticals Inc.'s filings include Mr. Raykov, Mr. Hackman, Dr. David M. Levinson, Dr. Frederick W. Telling, Dr. Adrian J. Wildfire and 3 others.
What are the main risk factors for Fennec Pharmaceuticals Inc. stock?
Of FENC's 24 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Fennec Pharmaceuticals Inc.?
Forward guidance and predictions for Fennec Pharmaceuticals Inc. are extracted from SEC filings as they are enriched.